Loading stock data…
Acurx Pharmaceuticals (ACXP)
$1.43+0.01 (+0.70%)
After Hours$1.46+0.03 (+2.10%)· Last close Sep 8
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Acurx Pharmaceuticals, Inc. in the Healthcare sector is trading at $1.43 with a market capitalization of $7M. Wall Street consensus targets $17.00 (3 analysts), implying a +1088.8% move over the next 12 months. The stock is currently near its 52-week low of $1.31, remaining 40.2% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +1088.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$1.72M↓ | -$1.62M↑ | -$2.03M↑ | -$2.27M↓ | -$2.18M |
| Net Income | -$1.68M↓ | -$1.58M↑ | -$1.99M↑ | -$2.25M↓ | -$2.15M |
Peer Comparison
JNJUNHPFE
Fundamentals
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the po...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.70M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-106.92%
Volume
Today's trading volume
80,195
Recent News
Acurx Pharmaceuticals Inc (ACXP) (Q2 2026) Earnings Call Highlights: FDA Signals Potential ...
Company advances toward pivotal Phase 3 trial with conditional FDA guidance, while securing funding to support operations for at least one year.
Acurx Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Moby summary of Acurx Pharmaceuticals, Inc.'s Q2 2026 earnings call
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's Why
Acurx Pharmaceuticals (ACXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Acurx Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Moby summary of Acurx Pharmaceuticals, Inc.'s Q1 2026 earnings call
Is Acurx Pharmaceuticals (ACXP) Stock Outpacing Its Medical Peers This Year?
Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Apyx Medical (APYX) have performed compared to their sector so far this year.